These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12503030)

  • 1. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
    Camirand A; Lu Y; Pollak M
    Med Sci Monit; 2002 Dec; 8(12):BR521-6. PubMed ID: 12503030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
    J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
    Cornelissen B; McLarty K; Kersemans V; Reilly RM
    Nucl Med Biol; 2008 Aug; 35(6):645-53. PubMed ID: 18678349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.
    Lu Y; Zi X; Pollak M
    Int J Cancer; 2004 Jan; 108(3):334-41. PubMed ID: 14648698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
    Youngren JF; Gable K; Penaranda C; Maddux BA; Zavodovskaya M; Lobo M; Campbell M; Kerner J; Goldfine ID
    Breast Cancer Res Treat; 2005 Nov; 94(1):37-46. PubMed ID: 16142439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).
    Lu Y; Zi X; Zhao Y; Mascarenhas D; Pollak M
    J Natl Cancer Inst; 2001 Dec; 93(24):1852-7. PubMed ID: 11752009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
    Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
    Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.
    Chakraborty AK; Liang K; DiGiovanna MP
    Cancer Res; 2008 Mar; 68(5):1538-45. PubMed ID: 18316619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
    Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
    Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
    Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
    Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.
    Sanabria-Figueroa E; Donnelly SM; Foy KC; Buss MC; Castellino RC; Paplomata E; Taliaferro-Smith L; Kaumaya PT; Nahta R
    Mol Pharmacol; 2015 Feb; 87(2):150-61. PubMed ID: 25391374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
    Molina MA; Codony-Servat J; Albanell J; Rojo F; Arribas J; Baselga J
    Cancer Res; 2001 Jun; 61(12):4744-9. PubMed ID: 11406546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.